Sutton, Janice
Menten, Martin J.
Riedl, Sophie
Bogunović, Hrvoje http://orcid.org/0000-0002-9168-0894
Leingang, Oliver
Anders, Philipp http://orcid.org/0000-0003-1690-9043
Hagag, Ahmed M. http://orcid.org/0000-0002-3372-7885
Waldstein, Sebastian http://orcid.org/0000-0003-2899-6279
Wilson, Amber
Cree, Angela J. http://orcid.org/0000-0002-1987-8900
Traber, Ghislaine
Fritsche, Lars G. http://orcid.org/0000-0002-2110-1690
Scholl, Hendrik
Rueckert, Daniel
Schmidt-Erfurth, Ursula http://orcid.org/0000-0002-7788-7311
Sivaprasad, Sobha
Prevost, Toby
Lotery, Andrew http://orcid.org/0000-0001-5541-4305
Funding for this research was provided by:
Wellcome Trust (210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z, 210572/Z/18/Z)
Article History
Received: 4 February 2022
Revised: 27 April 2022
Accepted: 6 May 2022
First Online: 25 May 2022
Change Date: 11 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41433-022-02131-1
Competing interests
: AL is a consultant for Gyroscope Therapeutics Ltd, Eyebio, Complement Therapeutics, Novartis, Allergan, Apellis and Tarsus Pharmaceuticals. DR is a co-founder and shareholder of IXICO Plc. SS has attended advisory board meetings and received research grants and is a consultant for Genentech Inc./F. Hoffmann-La Roche Ltd, Allergen, Bayer and Novartis, Oxurion, Ophtea, Optos, Oculis, Apellis, Eyebio, Gyroscope. SW is a consultant to Bayer, Roche, Santen, Böhringer Ingelheim and Novartis. USE receives grant support from Genentech, Kodiak, Novartis, RetInSight and Roche and is a consultant for Apellis. HB has received research grants from Heidelberg Engineering and Apellis, and speaker fees from Bayer, Roche, and Apellis. HS is a member of the Scientific Advisory Board of: Astellas Pharma Global Development, Inc./Astellas Institute for Regenerative Medicine; Boehringer Ingelheim Pharma GmbH & Co; Gyroscope Therapeutics Ltd.; Janssen Research & Development, LLC (Johnson & Johnson); Novartis Pharma AG (CORE); Okuvision GmbH; and Third Rock Ventures, LLC. He is a consultant of Gerson Lehrman Group; Guidepoint Global, LLC; and Tenpoint Therapeutics Limited. HS is a member of the Data Monitoring and Safety Board/Committee of Belite Bio (CT2019-CTN-04690-1), ReNeuron Group Plc/Ora Inc. (NCT02464436), F. Hoffmann-La Roche Ltd (VELODROME trial, NCT04657289; DIAGRID trial, NCT05126966) and member of the Steering Committee of Novo Nordisk (FOCUS trial; NCT03811561). He is a co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) which receives funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel-Stadt.